Proportion of flagship products seen increasing

Published: 2004-11-24 07:00:00

Updated: 2004-11-24 07:00:00

Despite the sagging economy, the share of leading OTC products in the total sale of pharmaceutical firms (FY: December) in the third quarter of this year stood at more 10 percent, thus significantly improving the balance sheet of companies owing such products, according to data released by Yakup ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK